Improving the availability and use of health research information in LMICs (9) Why open access matters

12 February, 2020

I read the piece below and felt to share is at once as we engage in the debate on Access to Research Information, Open Access, etc, before the GHF Round Table conference next month in Geneva [http://www.hifa.org/news/hifa-invites-everyone-contribute-geneva-health-.... It says it all: READ ON Courtesy of open Pharma -

''''

Combatting the next outbreak: why open access matters [https://openpharma.blog/2020/02/11/combatting-the-next-outbreak-why-open...

by sarahsabir

As the Open Pharma position statement reaches over 100 endorsements, we share why open access is important for public health [https://www.theguardian.com/education/2020/jan/22/people-cant-learn-abou... and hear why publishing house Frontiers has endorsed the position statement.

With an estimated two-thirds of all research trapped behind paywalls, The Guardian discusses the impact that this has on public health. Free access to key papers warning about Ebola back in 1982 would have better prepared healthcare professionals and researchers for the Ebola epidemic between 2014 and 2016 [https://www.nytimes.com/2015/04/08/opinion/yes-we-were-warned-about-ebol..., thus potentially saving thousands of lives, as reported in an open letter by health researchers in Liberia. Fast forward to the present day, the outbreak of the 2019 novel coronavirus has prompted researchers, journals and funders to ensure that all medical findings are shared rapidly and are accessible to everyone in a bid to prevent further spread of the disease and to improve patient care [https://www.bmj.com/coronavirus]. This includes making all peer-reviewed research immediately open access and sharing relevant findings on preprint servers or platforms. But should we be waiting for the next outbreak to make these changes or should we start adopting open access policies now to combat current and future health risks?

The Open Pharma position statement on open access calls for all peer-reviewed research to be made freely available to anyone who needs it anywhere in the world. Since its launch in October 2019, it has gained widespread coverage from The Telegraph, Taylor & Francis, F1000Research (now part of the Taylor & Francis group), Future Science Group, ecancer, the International Society for Medical Publication Professionals and many more. It has received global endorsements from academics, pharma, publishers, agencies, patient advocates and patients. Now nearly four months on, the position statement has received over 100 individual, company and publisher endorsements in total!

In a recent coverage, gold open access publisher and Open Pharma position statement endorser Frontiers states that open science is the best way to leverage the results of research to help foster innovation and to benefit all. Data collected by Frontiers show that pharma-funded articles published open access in one of Frontiers’ 70 journals has a citation impact four times greater than that of other articles in the same field. With Frontiers being the fifth most-cited scholarly publisher in the world, it is clear to see that publishing open access generates more impact and reach within the scientific community. The proportion of pharma-funded open access papers has almost doubled between 2009 and 2016. However, to continue to push scientific boundaries and to generate an informed society through access to high-quality peer-reviewed publications, there is still more work to be done with publishers to allow authors of company-funded research outputs the same rights to publish open access as authors whose research is funded from other funding sources.

If you agree with our mission, you can read and endorse the Open Pharma position statement here https://openpharma.blog/position-statement-on-open-access/

Position statement on open access

Pharmaceutical companies, which fund approximately half of all biomedical research,1 are now leaders in the publ...

AFRICA CENTRE FOR CLINICAL GOVERNANCE RESEARCH & PATIENT SAFETY

@Health Resources International (HRI) WA.

National Implementing Organisation: 12-Pillar Clinical Governance

National Implementing Organisation: PACK Nigeria Programme for PHC

Publisher: Medical and Health Journals; Books and Periodicals.

Nigeria: 8 Amaku Street, State Housing & 20 Eta Agbor Road, Calabar.

Tel: +234 (0) 8063600642

Website: www.hriwestafrica.com email: jneana@yahoo.co.uk ; hriwestafrica@gmail.com

HIFA profile: Joseph Ana is the Lead Consultant and Trainer at the Africa Centre for Clinical Governance Research and Patient Safety in Calabar, Nigeria. In 2015 he won the NMA Award of Excellence for establishing 12-Pillar Clinical Governance, Quality and Safety initiative in Nigeria. He has been the pioneer Chairman of the Nigerian Medical Association (NMA) National Committee on Clinical Governance and Research since 2012. He is also Chairman of the Quality & Performance subcommittee of the Technical Working Group for the implementation of the Nigeria Health Act. He is a pioneer Trustee-Director of the NMF (Nigerian Medical Forum) which took the BMJ to West Africa in 1995. He is particularly interested in strengthening health systems for quality and safety in LMICs. He has written Five books on the 12-Pillar Clinical Governance for LMICs, including a TOOLS for Implementation. He established the Department of Clinical Governance, Servicom & e-health in the Cross River State Ministry of Health, Nigeria in 2007. Website: www.hriwestafrica.com Joseph is a member of the HIFA Steering Group and the HIFA working group on Community Health Workers.

http://www.hifa.org/support/members/joseph-0

http://www.hifa.org/people/steering-group

Email: jneana AT yahoo.co.uk